In vitro experiments using STC-1 cells as enteroendocrine cells demonstrated that ICG-001, a selective inhibitor of Wnt/catenin signaling, dose-dependently reduced proglucagon gene expression
References: A Brave New World: Therapeutic Area Deep Dives on Obesity This blog is part of a new series exploring a range of topics in the obesity market, including: market size and scope, impact of payer controls, activity in non-traditional channels, patient behavior, GLP-1 impact, HCP responses, the policy landscape, pharmacy economics, and the outlook for the future of GLP-1
This concern was further highlighted by an analysis of the US FDA adverse events database
Our team provides medical evaluations, prescribes your treatment, and supports you with regular check-insall from the comfort of your home
Related research context Retatrutide is part of the GLP-1/GIP/glucagon triple-receptor agonist metabolic research class
When GLP-1 binds to GLP-1R, it: Stimulates insulin secretion in the pancreas to regulate blood glucose levels